20+ years of transformation, digital/IT and transaction experience
Expertise in complex supply chain management and operational issues
Focuses on the consumer-packaged goods, pharma and medical device industries
London
Twitter
LinkedIn
Copied!
Jan Diederichsen is a Senior Director with Alvarez & Marsal Corporate Performance Improvement in London. He brings more than 20 years of transformation, digital/IT and transaction experience in the consumer-packaged goods, pharma and medical device industries.
Mr. Diederichsen specializes in helping global corporations and private equity firms deliver transactions, turnaround programs and transformations covering complex supply chain management (SCM) and operational issues, technology and digital thought leadership, technology aspects of M&A, and operational and commercial due diligence.
Prior to joining A&M, Mr. Diederichsen conducted the buy-side operational and IT due diligence for the acquisition of several contract development and manufacturing organization (CDMO) sites in Europe and the U.S. He conducted in-person visits to evaluate operational, manufacturing and quality aspects, assessed IT applications and infrastructure, and executed an ALCOA+ based data integrity assessment to identify current maturity and needs for the post-acquisition phase.
Previously, Mr. Diederichsen led the SCM and digital transformation for one of the largest Eastern European pharma companies. He did a diagnostic of their value chain that addressed major cost reduction and transformation objectives related to inventory reduction, missed sales reduction and cost-to-serve optimization by reducing inventory by 10 percent, establishing S&OP governance, and redesigning the supply chain, improving cost-to-serve by 15 percent.
Mr. Diederichsen earned a bachelor’s degree in business and an MBA (operations and SCM focus) from the University of Wales.
A&M’s EMEA Healthcare & Life Sciences and Ops & Supply Chain teams have shared their predictions for CDMOs in 2030, and their perspectives on what CDMOs should be addressing now to achieve success in the future.
As global challenges continue, asset-light pharmaceutical companies will remain under increased pressure for the rest of 2022 and beyond. How can asset-light companies create value in a disrupted market? A&M shares 5-value levers for asset-light pharmaceutical businesses.
Shocks to global supply chains are increasing in frequency and severity. Russia’s invasion of Ukraine, new Covid outbreaks in China and rising interest rates in the US are occurring at once with ramifications for global trade. What steps can companies take to improve supply chain resilience.
Many Med Tech companies are still experiencing challenges as we move into a post-pandemic world. The cost of distribution has increased substantially, working capital has exploded, service levels have deteriorated, and profitability has suffered. A&M’s Healthcare & Life Sciences team set out approaches to adapt to the new environment, while achieving up to 3-5 percentage points improvement of EBITDA.
Latest insightsThe latest insights from Jan Diederichsen's team
